Pioneering a new era of longevity science

Rubedo Lead Drug Candidate RLS-1496 Will Be the First GPX4 Modulator to Enter Phase I Clinical Trials

Rubedo Life Sciences is an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells. Its unique approach to drug discovery allows them to precisely identify and selectively target pathologic and senescent “zombie” cells, which are known to release harmful substances, damage healthy cells, and accelerate the aging process. These inflammaging zombie cells play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic, and other chronic disorders and age-related diseases.

Its lead drug candidate, RLS-1496, a potential first-in-class, disease-altering GPX4 modulator, will be the first GPX4 modulator to enter Phase I clinical trials (April 2025) ahead of multiple biotech and leading pharmaceutical companies, putting Rubedo at the forefront of this new era in longevity science